Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

6.290 -0.130 (-2.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Travere Therapeutics Inc

< Previous 1 2 Next >
Travere Therapeutics to Report First Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2023 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Third Quarter 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
Data support the Company’s lead investigational product candidate sparsentan 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Third Quarter 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
From Vifor Pharma Group
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.